ID   KPCD_HUMAN              Reviewed;         676 AA.
AC   Q05655; B0KZ81; B2R834; Q15144; Q86XJ6;
DT   01-JUN-1994, integrated into UniProtKB/Swiss-Prot.
DT   02-SEP-2008, sequence version 2.
DT   12-OCT-2022, entry version 233.
DE   RecName: Full=Protein kinase C delta type {ECO:0000305};
DE            EC=2.7.11.13 {ECO:0000269|PubMed:12649167, ECO:0000269|PubMed:18285462, ECO:0000269|PubMed:34593629};
DE   AltName: Full=Tyrosine-protein kinase PRKCD;
DE            EC=2.7.10.2;
DE   AltName: Full=nPKC-delta;
DE   Contains:
DE     RecName: Full=Protein kinase C delta type regulatory subunit;
DE   Contains:
DE     RecName: Full=Protein kinase C delta type catalytic subunit;
DE     AltName: Full=Sphingosine-dependent protein kinase-1;
DE              Short=SDK1;
GN   Name=PRKCD {ECO:0000312|HGNC:HGNC:9399};
GN   Synonyms=PKCD {ECO:0000303|PubMed:17303575};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANTS SER-375 AND MET-593.
RC   TISSUE=Liver;
RX   PubMed=8357834; DOI=10.1016/0167-4781(93)90111-p;
RA   Aris J.P., Basta P.V., Holmes W.D., Ballas L.M., Moomaw C., Rankl N.B.,
RA   Blobel G., Loomis C.R., Burns D.J.;
RT   "Molecular and biochemical characterization of a recombinant human PKC-
RT   delta family member.";
RL   Biochim. Biophys. Acta 1174:171-181(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-365 (ISOFORM 1).
RC   TISSUE=Hippocampus;
RA   Hug H.;
RT   "Partial cDNA Sequence of human protein kinase C delta.";
RL   Submitted (MAR-1993) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 51-676 (ISOFORM 1).
RX   PubMed=9427282; DOI=10.1046/j.1365-2443.1997.1470346.x;
RA   Nomoto S., Watanabe Y., Ninomiya-Tsuji J., Yang L.-X., Kikuchi K.,
RA   Hagiwara M., Hidaka H., Matsumoto K., Irie K.;
RT   "Functional analyses of mammalian protein kinase C isozymes in budding
RT   yeast and mammalian fibroblasts.";
RL   Genes Cells 2:601-614(1997).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 224-371 (ISOFORM 2).
RX   PubMed=18092819; DOI=10.1021/bi7019782;
RA   Jiang K., Apostolatos A.H., Ghansah T., Watson J.E., Vickers T.,
RA   Cooper D.R., Epling-Burnette P.K., Patel N.A.;
RT   "Identification of a novel antiapoptotic human protein kinase C delta
RT   isoform, PKCdeltaVIII in NT2 cells.";
RL   Biochemistry 47:787-797(2008).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 432-533 (ISOFORM 1), AND VARIANT VAL-494.
RX   PubMed=7988719; DOI=10.1016/0014-5793(94)01202-4;
RA   Palmer R.H., Ridden J., Parker P.J.;
RT   "Identification of multiple, novel, protein kinase C-related gene
RT   products.";
RL   FEBS Lett. 356:5-8(1994).
RN   [9]
RP   FUNCTION.
RX   PubMed=11748588; DOI=10.1002/jcp.10022;
RA   Bankers-Fulbright J.L., Kita H., Gleich G.J., O'Grady S.M.;
RT   "Regulation of human eosinophil NADPH oxidase activity: a central role for
RT   PKCdelta.";
RL   J. Cell. Physiol. 189:306-315(2001).
RN   [10]
RP   MUTAGENESIS OF THR-507.
RX   PubMed=11772397; DOI=10.1042/bj3610255;
RA   Liu Y., Graham C., Li A., Fisher R.J., Shaw S.;
RT   "Phosphorylation of the protein kinase C-theta activation loop and
RT   hydrophobic motif regulates its kinase activity, but only activation loop
RT   phosphorylation is critical to in vivo nuclear-factor-kappaB induction.";
RL   Biochem. J. 361:255-265(2002).
RN   [11]
RP   INTERACTION WITH PDPK1, AND PHOSPHORYLATION.
RX   PubMed=11781095; DOI=10.1021/bi010719z;
RA   Hodgkinson C.P., Sale G.J.;
RT   "Regulation of both PDK1 and the phosphorylation of PKC-zeta and -delta by
RT   a C-terminal PRK2 fragment.";
RL   Biochemistry 41:561-569(2002).
RN   [12]
RP   INTERACTION WITH MUC1, AND FUNCTION.
RX   PubMed=11877440; DOI=10.1074/jbc.m200436200;
RA   Ren J., Li Y., Kufe D.;
RT   "Protein kinase C delta regulates function of the DF3/MUC1 carcinoma
RT   antigen in beta-catenin signaling.";
RL   J. Biol. Chem. 277:17616-17622(2002).
RN   [13]
RP   FUNCTION, CATALYTIC ACTIVITY, INTERACTION WITH PLSC3, BIOPHYSICOCHEMICAL
RP   PROPERTIES, AND SUBCELLULAR LOCATION.
RX   PubMed=12649167;
RA   Liu J., Chen J., Dai Q., Lee R.M.;
RT   "Phospholipid scramblase 3 is the mitochondrial target of protein kinase C
RT   delta-induced apoptosis.";
RL   Cancer Res. 63:1153-1156(2003).
RN   [14]
RP   INTERACTION WITH RAD9A.
RX   PubMed=12628935; DOI=10.1093/emboj/cdg134;
RA   Yoshida K., Wang H.-G., Miki Y., Kufe D.;
RT   "Protein kinase Cdelta is responsible for constitutive and DNA damage-
RT   induced phosphorylation of Rad9.";
RL   EMBO J. 22:1431-1441(2003).
RN   [15]
RP   FUNCTION, SUBCELLULAR LOCATION, AND PHOSPHORYLATION AT TYR-155.
RX   PubMed=15774464; DOI=10.1074/jbc.m501374200;
RA   Okhrimenko H., Lu W., Xiang C., Ju D., Blumberg P.M., Gomel R.,
RA   Kazimirsky G., Brodie C.;
RT   "Roles of tyrosine phosphorylation and cleavage of protein kinase Cdelta in
RT   its protective effect against tumor necrosis factor-related apoptosis
RT   inducing ligand-induced apoptosis.";
RL   J. Biol. Chem. 280:23643-23652(2005).
RN   [16]
RP   FUNCTION IN PLATELET AGGREGATION, AND INTERACTION WITH VASP.
RX   PubMed=16940418; DOI=10.1182/blood-2006-05-023739;
RA   Pula G., Schuh K., Nakayama K., Nakayama K.I., Walter U., Poole A.W.;
RT   "PKCdelta regulates collagen-induced platelet aggregation through
RT   inhibition of VASP-mediated filopodia formation.";
RL   Blood 108:4035-4044(2006).
RN   [17]
RP   PHOSPHORYLATION AT TYR-313 AND TYR-567.
RX   PubMed=17570831; DOI=10.1042/bj20070244;
RA   Hall K.J., Jones M.L., Poole A.W.;
RT   "Coincident regulation of PKCdelta in human platelets by phosphorylation of
RT   Tyr311 and Tyr565 and phospholipase C signalling.";
RL   Biochem. J. 406:501-509(2007).
RN   [18]
RP   SUBCELLULAR LOCATION, AUTOPHOSPHORYLATION, PHOSPHORYLATION AT SER-299;
RP   SER-302 AND SER-304, AND MUTAGENESIS OF SER-299.
RX   PubMed=17603046; DOI=10.1016/j.febslet.2007.06.035;
RA   Durgan J., Michael N., Totty N., Parker P.J.;
RT   "Novel phosphorylation site markers of protein kinase C delta activation.";
RL   FEBS Lett. 581:3377-3381(2007).
RN   [19]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=17303575; DOI=10.1074/jbc.m609424200;
RA   Zeidan Y.H., Hannun Y.A.;
RT   "Activation of acid sphingomyelinase by protein kinase Cdelta-mediated
RT   phosphorylation.";
RL   J. Biol. Chem. 282:11549-11561(2007).
RN   [20]
RP   SUBCELLULAR LOCATION.
RX   PubMed=17579121; DOI=10.1158/1541-7786.mcr-06-0255;
RA   Gomel R., Xiang C., Finniss S., Lee H.K., Lu W., Okhrimenko H., Brodie C.;
RT   "The localization of protein kinase Cdelta in different subcellular sites
RT   affects its proapoptotic and antiapoptotic functions and the activation of
RT   distinct downstream signaling pathways.";
RL   Mol. Cancer Res. 5:627-639(2007).
RN   [21]
RP   PHOSPHORYLATION AT THR-50; THR-141; SER-304; THR-451; SER-506; THR-507 AND
RP   SER-664, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=17965192; DOI=10.1110/ps.072874607;
RA   Welman A., Griffiths J.R., Whetton A.D., Dive C.;
RT   "Protein kinase C delta is phosphorylated on five novel Ser/Thr sites
RT   following inducible overexpression in human colorectal cancer cells.";
RL   Protein Sci. 16:2711-2715(2007).
RN   [22]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Platelet;
RX   PubMed=18088087; DOI=10.1021/pr0704130;
RA   Zahedi R.P., Lewandrowski U., Wiesner J., Wortelkamp S., Moebius J.,
RA   Schuetz C., Walter U., Gambaryan S., Sickmann A.;
RT   "Phosphoproteome of resting human platelets.";
RL   J. Proteome Res. 7:526-534(2008).
RN   [23]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-299; TYR-313; SER-503;
RP   SER-654; SER-658 AND SER-664, AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of the
RT   kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [24]
RP   FUNCTION, CATALYTIC ACTIVITY, AND SUBCELLULAR LOCATION.
RX   PubMed=18285462; DOI=10.1128/mcb.01530-07;
RA   Doller A., Akool E.-S., Huwiler A., Mueller R., Radeke H.H.,
RA   Pfeilschifter J., Eberhardt W.;
RT   "Posttranslational modification of the AU-rich element binding protein HuR
RT   by protein kinase Cdelta elicits angiotensin II-induced stabilization and
RT   nuclear export of cyclooxygenase 2 mRNA.";
RL   Mol. Cell. Biol. 28:2608-2625(2008).
RN   [25]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-130; SER-302; SER-304;
RP   SER-307 AND SER-664, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [26]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [27]
RP   FUNCTION IN PLATELET RESPONSE.
RX   PubMed=19587372; DOI=10.1182/blood-2008-11-188516;
RA   Chari R., Kim S., Murugappan S., Sanjay A., Daniel J.L., Kunapuli S.P.;
RT   "Lyn, PKC-delta, SHIP-1 interactions regulate GPVI-mediated platelet-dense
RT   granule secretion.";
RL   Blood 114:3056-3063(2009).
RN   [28]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-218; TYR-313 AND SER-664, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [29]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-313 AND SER-664, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [30]
RP   FUNCTION IN PHOSPHORYLATION OF NCF1, AND PHOSPHORYLATION AT THR-507 AND
RP   SER-645.
RX   PubMed=19801500; DOI=10.1189/jlb.0408230;
RA   Kilpatrick L.E., Sun S., Li H., Vary T.C., Korchak H.M.;
RT   "Regulation of TNF-induced oxygen radical production in human neutrophils:
RT   role of delta-PKC.";
RL   J. Leukoc. Biol. 87:153-164(2010).
RN   [31]
RP   REVIEW ON FUNCTION.
RX   PubMed=12473183; DOI=10.1093/oxfordjournals.jbchem.a003294;
RA   Kikkawa U., Matsuzaki H., Yamamoto T.;
RT   "Protein kinase C delta (PKC delta): activation mechanisms and functions.";
RL   J. Biochem. 132:831-839(2002).
RN   [32]
RP   REVIEW ON FUNCTION.
RX   PubMed=20002545; DOI=10.1111/j.1538-7836.2009.03722.x;
RA   Harper M.T., Poole A.W.;
RT   "Diverse functions of protein kinase C isoforms in platelet activation and
RT   thrombus formation.";
RL   J. Thromb. Haemost. 8:454-462(2010).
RN   [33]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-304; TYR-374; SER-645 AND
RP   SER-664, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [34]
RP   REVIEW ON FUNCTION.
RX   PubMed=21103796; DOI=10.1100/tsw.2010.214;
RA   Basu A., Pal D.;
RT   "Two faces of protein kinase Cdelta: the contrasting roles of PKCdelta in
RT   cell survival and cell death.";
RL   ScientificWorldJournal 10:2272-2284(2010).
RN   [35]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [36]
RP   REVIEW ON FUNCTION.
RX   PubMed=21810427; DOI=10.1016/j.yjmcc.2011.07.013;
RA   Duquesnes N., Lezoualc'h F., Crozatier B.;
RT   "PKC-delta and PKC-epsilon: Foes of the same family or strangers?";
RL   J. Mol. Cell. Cardiol. 51:665-673(2011).
RN   [37]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-304 AND SER-645, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [38]
RP   REVIEW.
RX   PubMed=22918451; DOI=10.1007/s00005-012-0188-8;
RA   Zhao M., Xia L., Chen G.Q.;
RT   "Protein kinase cdelta in apoptosis: a brief overview.";
RL   Arch. Immunol. Ther. Exp. 60:361-372(2012).
RN   [39]
RP   INVOLVEMENT IN ALPS3.
RX   PubMed=23319571; DOI=10.1182/blood-2012-10-460741;
RA   Salzer E., Santos-Valente E., Klaver S., Ban S.A., Emminger W.,
RA   Prengemann N.K., Garncarz W., Mullauer L., Kain R., Boztug H., Heitger A.,
RA   Arbeiter K., Eitelberger F., Seidel M.G., Holter W., Pollak A., Pickl W.F.,
RA   Forster-Waldl E., Boztug K.;
RT   "B-cell deficiency and severe autoimmunity caused by deficiency of protein
RT   kinase C delta.";
RL   Blood 121:3112-3116(2013).
RN   [40]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-141; SER-299; SER-302;
RP   SER-304; SER-307; SER-503 AND SER-664, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [41]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-664, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [42]
RP   INTERACTION WITH PRKD2.
RX   PubMed=28428613; DOI=10.1038/s41598-017-00800-w;
RA   Cobbaut M., Derua R., Doeppler H., Lou H.J., Vandoninck S., Storz P.,
RA   Turk B.E., Seufferlein T., Waelkens E., Janssens V., Van Lint J.;
RT   "Differential regulation of PKD isoforms in oxidative stress conditions
RT   through phosphorylation of a conserved Tyr in the P+1 loop.";
RL   Sci. Rep. 7:887-887(2017).
RN   [43]
RP   CATALYTIC ACTIVITY, ACTIVITY REGULATION, AND INTERACTION WITH PRKCH
RP   UPSTREAM OPEN READING FRAME 2.
RX   PubMed=34593629; DOI=10.1073/pnas.2018899118;
RA   Jayaram D.R., Frost S., Argov C., Liju V.B., Anto N.P., Muraleedharan A.,
RA   Ben-Ari A., Sinay R., Smoly I., Novoplansky O., Isakov N., Toiber D.,
RA   Keasar C., Elkabets M., Yeger-Lotem E., Livneh E.;
RT   "Unraveling the hidden role of a uORF-encoded peptide as a kinase inhibitor
RT   of PKCs.";
RL   Proc. Natl. Acad. Sci. U.S.A. 118:0-0(2021).
RN   [44]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 1-123 IN COMPLEX WITH
RP   PHOSPHOTYROSINE-CONTAINING PEPTIDE, AND INTERACTION WITH CDCP1.
RX   PubMed=15851033; DOI=10.1016/j.cell.2005.02.019;
RA   Benes C.H., Wu N., Elia A.E.H., Dharia T., Cantley L.C., Soltoff S.P.;
RT   "The C2 domain of PKCdelta is a phosphotyrosine binding domain.";
RL   Cell 121:271-280(2005).
RN   [45]
RP   STRUCTURE BY NMR OF 149-218.
RG   RIKEN structural genomics initiative (RSGI);
RT   "Solution structure of the first phorbol esters/diacylglycerol binding
RT   domain of human protein kinase C, delta.";
RL   Submitted (APR-2008) to the PDB data bank.
CC   -!- FUNCTION: Calcium-independent, phospholipid- and diacylglycerol (DAG)-
CC       dependent serine/threonine-protein kinase that plays contrasting roles
CC       in cell death and cell survival by functioning as a pro-apoptotic
CC       protein during DNA damage-induced apoptosis, but acting as an anti-
CC       apoptotic protein during cytokine receptor-initiated cell death, is
CC       involved in tumor suppression as well as survival of several cancers,
CC       is required for oxygen radical production by NADPH oxidase and acts as
CC       positive or negative regulator in platelet functional responses
CC       (PubMed:21810427, PubMed:21406692). Negatively regulates B cell
CC       proliferation and also has an important function in self-antigen
CC       induced B cell tolerance induction (By similarity). Upon DNA damage,
CC       activates the promoter of the death-promoting transcription factor
CC       BCLAF1/Btf to trigger BCLAF1-mediated p53/TP53 gene transcription and
CC       apoptosis (PubMed:21810427, PubMed:21406692). In response to oxidative
CC       stress, interact with and activate CHUK/IKKA in the nucleus, causing
CC       the phosphorylation of p53/TP53 (PubMed:21810427, PubMed:21406692). In
CC       the case of ER stress or DNA damage-induced apoptosis, can form a
CC       complex with the tyrosine-protein kinase ABL1 which trigger apoptosis
CC       independently of p53/TP53 (PubMed:21810427, PubMed:21406692). In
CC       cytosol can trigger apoptosis by activating MAPK11 or MAPK14,
CC       inhibiting AKT1 and decreasing the level of X-linked inhibitor of
CC       apoptosis protein (XIAP), whereas in nucleus induces apoptosis via the
CC       activation of MAPK8 or MAPK9. Upon ionizing radiation treatment, is
CC       required for the activation of the apoptosis regulators BAX and BAK,
CC       which trigger the mitochondrial cell death pathway. Can phosphorylate
CC       MCL1 and target it for degradation which is sufficient to trigger for
CC       BAX activation and apoptosis. Is required for the control of cell cycle
CC       progression both at G1/S and G2/M phases. Mediates phorbol 12-myristate
CC       13-acetate (PMA)-induced inhibition of cell cycle progression at G1/S
CC       phase by up-regulating the CDK inhibitor CDKN1A/p21 and inhibiting the
CC       cyclin CCNA2 promoter activity. In response to UV irradiation can
CC       phosphorylate CDK1, which is important for the G2/M DNA damage
CC       checkpoint activation (By similarity). Can protect glioma cells from
CC       the apoptosis induced by TNFSF10/TRAIL, probably by inducing increased
CC       phosphorylation and subsequent activation of AKT1 (PubMed:15774464). Is
CC       highly expressed in a number of cancer cells and promotes cell survival
CC       and resistance against chemotherapeutic drugs by inducing cyclin D1
CC       (CCND1) and hyperphosphorylation of RB1, and via several pro-survival
CC       pathways, including NF-kappa-B, AKT1 and MAPK1/3 (ERK1/2). Involved in
CC       antifungal immunity by mediating phosphorylation and activation of
CC       CARD9 downstream of C-type lectin receptors activation, promoting
CC       interaction between CARD9 and BCL10, followed by activation of NF-
CC       kappa-B and MAP kinase p38 pathways (By similarity). Can also act as
CC       tumor suppressor upon mitogenic stimulation with PMA or TPA. In N-
CC       formyl-methionyl-leucyl-phenylalanine (fMLP)-treated cells, is required
CC       for NCF1 (p47-phox) phosphorylation and activation of NADPH oxidase
CC       activity, and regulates TNF-elicited superoxide anion production in
CC       neutrophils, by direct phosphorylation and activation of NCF1 or
CC       indirectly through MAPK1/3 (ERK1/2) signaling pathways
CC       (PubMed:19801500). May also play a role in the regulation of NADPH
CC       oxidase activity in eosinophil after stimulation with IL5, leukotriene
CC       B4 or PMA (PubMed:11748588). In collagen-induced platelet aggregation,
CC       acts a negative regulator of filopodia formation and actin
CC       polymerization by interacting with and negatively regulating VASP
CC       phosphorylation (PubMed:16940418). Downstream of PAR1, PAR4 and
CC       CD36/GP4 receptors, regulates differentially platelet dense granule
CC       secretion; acts as a positive regulator in PAR-mediated granule
CC       secretion, whereas it negatively regulates CD36/GP4-mediated granule
CC       release (PubMed:19587372). Phosphorylates MUC1 in the C-terminal and
CC       regulates the interaction between MUC1 and beta-catenin
CC       (PubMed:11877440). The catalytic subunit phosphorylates 14-3-3 proteins
CC       (YWHAB, YWHAZ and YWHAH) in a sphingosine-dependent fashion (By
CC       similarity). Phosphorylates ELAVL1 in response to angiotensin-2
CC       treatment (PubMed:18285462). Phosphorylates mitochondrial phospholipid
CC       scramblase 3 (PLSCR3), resulting in increased cardiolipin expression on
CC       the mitochondrial outer membrane which facilitates apoptosis
CC       (PubMed:12649167). Phosphorylates SMPD1 which induces SMPD1 secretion
CC       (PubMed:17303575). {ECO:0000250|UniProtKB:P28867,
CC       ECO:0000269|PubMed:11748588, ECO:0000269|PubMed:11877440,
CC       ECO:0000269|PubMed:12649167, ECO:0000269|PubMed:15774464,
CC       ECO:0000269|PubMed:16940418, ECO:0000269|PubMed:17303575,
CC       ECO:0000269|PubMed:18285462, ECO:0000269|PubMed:19587372,
CC       ECO:0000269|PubMed:19801500, ECO:0000303|PubMed:21406692,
CC       ECO:0000303|PubMed:21810427}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.13;
CC         Evidence={ECO:0000269|PubMed:18285462, ECO:0000269|PubMed:34593629};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060,
CC         Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.11.13; Evidence={ECO:0000269|PubMed:12649167,
CC         ECO:0000269|PubMed:18285462, ECO:0000269|PubMed:34593629};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-tyrosyl-[protein] = ADP + H(+) + O-phospho-L-tyrosyl-
CC         [protein]; Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA-
CC         COMP:10137, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858,
CC         ChEBI:CHEBI:82620, ChEBI:CHEBI:456216; EC=2.7.10.2;
CC         Evidence={ECO:0000255|PROSITE-ProRule:PRU10027};
CC   -!- ACTIVITY REGULATION: Novel PKCs (PRKCD, PRKCE, PRKCH and PRKCQ) are
CC       calcium-insensitive, but activated by diacylglycerol (DAG) and
CC       phosphatidylserine. Three specific sites; Thr-507 (activation loop of
CC       the kinase domain), Ser-645 (turn motif) and Ser-664 (hydrophobic
CC       region), need to be phosphorylated for its full activation. Activated
CC       by caspase-3 (CASP3) cleavage during apoptosis. After cleavage, the
CC       pseudosubstrate motif in the regulatory subunit is released from the
CC       substrate recognition site of the catalytic subunit, which enables
CC       PRKCD to become constitutively activated. The catalytic subunit which
CC       displays properties of a sphingosine-dependent protein kinase is
CC       activated by D-erythro-sphingosine (Sph) or N,N-dimethyl-D-
CC       erythrosphingosine (DMS) or N,N,N-trimethyl-D-erythrosphingosine (TMS),
CC       but not by ceramide or Sph-1-P and is strongly inhibited by
CC       phosphatidylserine (By similarity). Inhibited by PRKCH upstream open
CC       reading frame 2 (PubMed:34593629). {ECO:0000250,
CC       ECO:0000269|PubMed:34593629}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=10.5 nM for PLSC3 {ECO:0000269|PubMed:12649167};
CC   -!- SUBUNIT: Interacts with PDPK1 (via N-terminal region)
CC       (PubMed:11781095). Interacts with RAD9A (PubMed:12628935). Interacts
CC       with CDCP1 (PubMed:15851033). Interacts with MUC1 (PubMed:11877440).
CC       Interacts with VASP (PubMed:16940418). Interacts with CAVIN3 (By
CC       similarity). Interacts with PRKD2 (via N-terminus and zing-finger
CC       domain 1 and 2) in response to oxidative stress; the interaction is
CC       independent of PRKD2 tyrosine phosphorylation (PubMed:28428613).
CC       Interacts with PLSC3; interaction is enhanced by UV irradiation
CC       (PubMed:12649167). Interacts with PRKCH upstream open reading frame 2;
CC       the interaction leads to inhibition of kinase activity
CC       (PubMed:34593629). {ECO:0000250|UniProtKB:P28867,
CC       ECO:0000269|PubMed:11781095, ECO:0000269|PubMed:11877440,
CC       ECO:0000269|PubMed:12628935, ECO:0000269|PubMed:12649167,
CC       ECO:0000269|PubMed:15851033, ECO:0000269|PubMed:16940418,
CC       ECO:0000269|PubMed:28428613, ECO:0000269|PubMed:34593629}.
CC   -!- INTERACTION:
CC       Q05655; P05067: APP; NbExp=3; IntAct=EBI-704279, EBI-77613;
CC       Q05655; Q9BXL7: CARD11; NbExp=7; IntAct=EBI-704279, EBI-7006141;
CC       Q05655; Q9NR28: DIABLO; NbExp=4; IntAct=EBI-704279, EBI-517508;
CC       Q05655; P06241: FYN; NbExp=5; IntAct=EBI-704279, EBI-515315;
CC       Q05655; P17677: GAP43; NbExp=4; IntAct=EBI-704279, EBI-1267511;
CC       Q05655; C6GKH1: IL32; NbExp=3; IntAct=EBI-704279, EBI-9547476;
CC       Q05655; P24001-2: IL32; NbExp=7; IntAct=EBI-704279, EBI-8800907;
CC       Q05655; P19878: NCF2; NbExp=3; IntAct=EBI-704279, EBI-489611;
CC       Q05655; P11388: TOP2A; NbExp=10; IntAct=EBI-704279, EBI-539628;
CC       Q05655; P04637: TP53; NbExp=4; IntAct=EBI-704279, EBI-366083;
CC       Q05655; Q9H3D4: TP63; NbExp=2; IntAct=EBI-704279, EBI-2337775;
CC       Q05655; Q9UBQ0-2: VPS29; NbExp=3; IntAct=EBI-704279, EBI-11141397;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:15774464,
CC       ECO:0000269|PubMed:17303575, ECO:0000269|PubMed:17603046,
CC       ECO:0000269|PubMed:18285462}. Cytoplasm, perinuclear region
CC       {ECO:0000269|PubMed:12649167, ECO:0000269|PubMed:15774464,
CC       ECO:0000269|PubMed:17603046}. Nucleus {ECO:0000269|PubMed:15774464,
CC       ECO:0000269|PubMed:17603046, ECO:0000269|PubMed:18285462}. Cell
CC       membrane {ECO:0000269|PubMed:17303575, ECO:0000269|PubMed:17603046};
CC       Peripheral membrane protein {ECO:0000305|PubMed:17603046}.
CC       Mitochondrion {ECO:0000269|PubMed:12649167}. Endomembrane system
CC       {ECO:0000269|PubMed:17303575}. Note=Translocates to the mitochondria
CC       upon apoptotic stimulation. Upon activation, translocates to the plasma
CC       membrane followed by partial location to the endolysosomes
CC       (PubMed:17303575). {ECO:0000269|PubMed:12649167,
CC       ECO:0000269|PubMed:17303575}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q05655-1; Sequence=Displayed;
CC       Name=2; Synonyms=PKCdeltaVIII;
CC         IsoId=Q05655-2; Sequence=VSP_043899;
CC   -!- DOMAIN: The C1 domain, containing the phorbol ester/DAG-type region 1
CC       (C1A) and 2 (C1B), is the diacylglycerol sensor.
CC   -!- DOMAIN: The C2 domain is a non-calcium binding domain. It binds
CC       proteins containing phosphotyrosine in a sequence-specific manner.
CC   -!- PTM: Autophosphorylated and/or phosphorylated at Thr-507, within the
CC       activation loop; phosphorylation at Thr-507 is not a prerequisite for
CC       enzymatic activity (PubMed:19801500). Autophosphorylated at Ser-299,
CC       Ser-302 and Ser-304 (PubMed:17603046). Upon TNFSF10/TRAIL treatment,
CC       phosphorylated at Tyr-155; phosphorylation is required for its
CC       translocation to the endoplasmic reticulum and cleavage by caspase-3
CC       (PubMed:15774464). Phosphorylated at Tyr-313, Tyr-334 and Tyr-567;
CC       phosphorylation of Tyr-313 and Tyr-567 following thrombin or zymosan
CC       stimulation potentiates its kinase activity (PubMed:17570831).
CC       Phosphorylated by protein kinase PDPK1; phosphorylation is inhibited by
CC       the apoptotic C-terminal cleavage product of PKN2 (PubMed:11781095).
CC       Phosphorylated at Tyr-313 through a SYK and SRC mechanism downstream of
CC       C-type lectin receptors activation, promoting its activation (By
CC       similarity). {ECO:0000250|UniProtKB:P28867,
CC       ECO:0000269|PubMed:11781095, ECO:0000269|PubMed:15774464,
CC       ECO:0000269|PubMed:17570831, ECO:0000269|PubMed:17603046,
CC       ECO:0000269|PubMed:19801500}.
CC   -!- PTM: Proteolytically cleaved into a catalytic subunit and a regulatory
CC       subunit by caspase-3 during apoptosis which results in kinase
CC       activation. {ECO:0000250}.
CC   -!- DISEASE: Autoimmune lymphoproliferative syndrome 3 (ALPS3)
CC       [MIM:615559]: A primary immunodeficiency characterized by antibody
CC       deficiency, hypogammaglobulinemia, recurrent bacterial infections and
CC       an inability to mount an antibody response to antigen. The defect
CC       results from a failure of B-cell differentiation and impaired secretion
CC       of immunoglobulins; the numbers of circulating B-cells is usually in
CC       the normal range, but can be low. CVID9 patients have B-cell deficiency
CC       and severe autoimmunity. {ECO:0000269|PubMed:23319571}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- MISCELLANEOUS: [Isoform 2]: Antiapoptotic isoform, resistant to
CC       caspase-3 cleavage. {ECO:0000305}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. AGC Ser/Thr
CC       protein kinase family. PKC subfamily. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/PRKCDID42901ch3p21.html";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; L07860; AAA03176.1; -; mRNA.
DR   EMBL; L07861; AAA03175.1; -; mRNA.
DR   EMBL; AK313216; BAG36031.1; -; mRNA.
DR   EMBL; CH471055; EAW65279.1; -; Genomic_DNA.
DR   EMBL; BC043350; AAH43350.1; -; mRNA.
DR   EMBL; Z22521; CAA80249.1; -; mRNA.
DR   EMBL; D10495; BAA01381.1; -; mRNA.
DR   EMBL; DQ516383; ABF68960.1; -; mRNA.
DR   CCDS; CCDS2870.1; -. [Q05655-1]
DR   PIR; S35704; S35704.
DR   RefSeq; NP_001303256.1; NM_001316327.1. [Q05655-1]
DR   RefSeq; NP_006245.2; NM_006254.3. [Q05655-1]
DR   RefSeq; NP_997704.1; NM_212539.1. [Q05655-1]
DR   RefSeq; XP_006713322.1; XM_006713259.2.
DR   RefSeq; XP_016862344.1; XM_017006855.1.
DR   RefSeq; XP_016862345.1; XM_017006856.1.
DR   PDB; 1YRK; X-ray; 1.70 A; A=1-123.
DR   PDB; 2YUU; NMR; -; A=149-218.
DR   PDBsum; 1YRK; -.
DR   PDBsum; 2YUU; -.
DR   AlphaFoldDB; Q05655; -.
DR   SMR; Q05655; -.
DR   BioGRID; 111566; 146.
DR   CORUM; Q05655; -.
DR   DIP; DIP-29954N; -.
DR   ELM; Q05655; -.
DR   IntAct; Q05655; 53.
DR   MINT; Q05655; -.
DR   STRING; 9606.ENSP00000378217; -.
DR   BindingDB; Q05655; -.
DR   ChEMBL; CHEMBL2996; -.
DR   DrugBank; DB04376; 13-Acetylphorbol.
DR   DrugBank; DB09096; Benzoyl peroxide.
DR   DrugBank; DB12010; Fostamatinib.
DR   DrugBank; DB05013; Ingenol mebutate.
DR   DrugBank; DB00675; Tamoxifen.
DR   DrugCentral; Q05655; -.
DR   GuidetoPHARMACOLOGY; 1485; -.
DR   iPTMnet; Q05655; -.
DR   PhosphoSitePlus; Q05655; -.
DR   BioMuta; PRKCD; -.
DR   DMDM; 205371776; -.
DR   CPTAC; CPTAC-1743; -.
DR   EPD; Q05655; -.
DR   jPOST; Q05655; -.
DR   MassIVE; Q05655; -.
DR   MaxQB; Q05655; -.
DR   PaxDb; Q05655; -.
DR   PeptideAtlas; Q05655; -.
DR   PRIDE; Q05655; -.
DR   ProteomicsDB; 58342; -. [Q05655-1]
DR   ProteomicsDB; 58343; -. [Q05655-2]
DR   Antibodypedia; 664; 1193 antibodies from 44 providers.
DR   DNASU; 5580; -.
DR   Ensembl; ENST00000330452.8; ENSP00000331602.3; ENSG00000163932.15. [Q05655-1]
DR   Ensembl; ENST00000394729.6; ENSP00000378217.2; ENSG00000163932.15. [Q05655-1]
DR   Ensembl; ENST00000650739.1; ENSP00000498623.1; ENSG00000163932.15. [Q05655-1]
DR   Ensembl; ENST00000652449.1; ENSP00000498400.1; ENSG00000163932.15. [Q05655-1]
DR   Ensembl; ENST00000654719.1; ENSP00000499558.1; ENSG00000163932.15. [Q05655-1]
DR   GeneID; 5580; -.
DR   KEGG; hsa:5580; -.
DR   MANE-Select; ENST00000330452.8; ENSP00000331602.3; NM_006254.4; NP_006245.2.
DR   UCSC; uc003dgl.4; human. [Q05655-1]
DR   CTD; 5580; -.
DR   DisGeNET; 5580; -.
DR   GeneCards; PRKCD; -.
DR   HGNC; HGNC:9399; PRKCD.
DR   HPA; ENSG00000163932; Low tissue specificity.
DR   MalaCards; PRKCD; -.
DR   MIM; 176977; gene.
DR   MIM; 615559; phenotype.
DR   neXtProt; NX_Q05655; -.
DR   OpenTargets; ENSG00000163932; -.
DR   Orphanet; 3261; Autoimmune lymphoproliferative syndrome.
DR   Orphanet; 300345; Autosomal systemic lupus erythematosus.
DR   Orphanet; 1572; Common variable immunodeficiency.
DR   PharmGKB; PA33763; -.
DR   VEuPathDB; HostDB:ENSG00000163932; -.
DR   eggNOG; KOG0694; Eukaryota.
DR   GeneTree; ENSGT00940000155327; -.
DR   HOGENOM; CLU_000288_54_4_1; -.
DR   InParanoid; Q05655; -.
DR   OMA; YPEWKSS; -.
DR   OrthoDB; 222529at2759; -.
DR   PhylomeDB; Q05655; -.
DR   TreeFam; TF102004; -.
DR   BRENDA; 2.7.11.13; 2681.
DR   PathwayCommons; Q05655; -.
DR   Reactome; R-HSA-111465; Apoptotic cleavage of cellular proteins.
DR   Reactome; R-HSA-111933; Calmodulin induced events.
DR   Reactome; R-HSA-114508; Effects of PIP2 hydrolysis.
DR   Reactome; R-HSA-1250196; SHC1 events in ERBB2 signaling.
DR   Reactome; R-HSA-1489509; DAG and IP3 signaling.
DR   Reactome; R-HSA-2029485; Role of phospholipids in phagocytosis.
DR   Reactome; R-HSA-418597; G alpha (z) signalling events.
DR   Reactome; R-HSA-450520; HuR (ELAVL1) binds and stabilizes mRNA.
DR   Reactome; R-HSA-5218921; VEGFR2 mediated cell proliferation.
DR   Reactome; R-HSA-5607764; CLEC7A (Dectin-1) signaling.
DR   Reactome; R-HSA-5668599; RHO GTPases Activate NADPH Oxidases.
DR   Reactome; R-HSA-6798695; Neutrophil degranulation.
DR   Reactome; R-HSA-877300; Interferon gamma signaling.
DR   Reactome; R-HSA-9755511; KEAP1-NFE2L2 pathway.
DR   SABIO-RK; Q05655; -.
DR   SignaLink; Q05655; -.
DR   SIGNOR; Q05655; -.
DR   BioGRID-ORCS; 5580; 17 hits in 1111 CRISPR screens.
DR   ChiTaRS; PRKCD; human.
DR   EvolutionaryTrace; Q05655; -.
DR   GeneWiki; PRKCD; -.
DR   GenomeRNAi; 5580; -.
DR   Pharos; Q05655; Tclin.
DR   PRO; PR:Q05655; -.
DR   Proteomes; UP000005640; Chromosome 3.
DR   RNAct; Q05655; protein.
DR   Bgee; ENSG00000163932; Expressed in monocyte and 148 other tissues.
DR   ExpressionAtlas; Q05655; baseline and differential.
DR   Genevisible; Q05655; HS.
DR   GO; GO:0035578; C:azurophil granule lumen; TAS:Reactome.
DR   GO; GO:0005911; C:cell-cell junction; IEA:Ensembl.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:UniProtKB.
DR   GO; GO:0036019; C:endolysosome; IDA:UniProtKB.
DR   GO; GO:0005783; C:endoplasmic reticulum; IDA:UniProtKB.
DR   GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0005739; C:mitochondrion; IEA:UniProtKB-SubCell.
DR   GO; GO:0016363; C:nuclear matrix; IEA:Ensembl.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004698; F:calcium-dependent protein kinase C activity; IEA:UniProtKB-EC.
DR   GO; GO:0004699; F:calcium-independent protein kinase C activity; TAS:BHF-UCL.
DR   GO; GO:0008047; F:enzyme activator activity; IDA:UniProtKB.
DR   GO; GO:0019899; F:enzyme binding; IDA:BHF-UCL.
DR   GO; GO:0043560; F:insulin receptor substrate binding; ISS:BHF-UCL.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0004715; F:non-membrane spanning protein tyrosine kinase activity; IEA:UniProtKB-EC.
DR   GO; GO:0004672; F:protein kinase activity; IDA:UniProtKB.
DR   GO; GO:0019901; F:protein kinase binding; IPI:UniProtKB.
DR   GO; GO:0004697; F:protein kinase C activity; EXP:Reactome.
DR   GO; GO:0106310; F:protein serine kinase activity; IDA:UniProtKB.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB.
DR   GO; GO:0032147; P:activation of protein kinase activity; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0006915; P:apoptotic process; IDA:UniProtKB.
DR   GO; GO:0042100; P:B cell proliferation; IEA:Ensembl.
DR   GO; GO:0060326; P:cell chemotaxis; IMP:UniProtKB.
DR   GO; GO:0007049; P:cell cycle; IEA:UniProtKB-KW.
DR   GO; GO:1904385; P:cellular response to angiotensin; IDA:UniProtKB.
DR   GO; GO:0070301; P:cellular response to hydrogen peroxide; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0071447; P:cellular response to hydroperoxide; IDA:UniProtKB.
DR   GO; GO:0034644; P:cellular response to UV; IDA:UniProtKB.
DR   GO; GO:0090398; P:cellular senescence; IMP:BHF-UCL.
DR   GO; GO:0042742; P:defense response to bacterium; ISS:UniProtKB.
DR   GO; GO:0038096; P:Fc-gamma receptor signaling pathway involved in phagocytosis; TAS:Reactome.
DR   GO; GO:0016064; P:immunoglobulin mediated immune response; IEA:Ensembl.
DR   GO; GO:0035556; P:intracellular signal transduction; IBA:GO_Central.
DR   GO; GO:0008631; P:intrinsic apoptotic signaling pathway in response to oxidative stress; TAS:ParkinsonsUK-UCL.
DR   GO; GO:0030837; P:negative regulation of actin filament polymerization; ISS:UniProtKB.
DR   GO; GO:0051490; P:negative regulation of filopodium assembly; ISS:UniProtKB.
DR   GO; GO:0034351; P:negative regulation of glial cell apoptotic process; IMP:UniProtKB.
DR   GO; GO:0050728; P:negative regulation of inflammatory response; IC:BHF-UCL.
DR   GO; GO:0046627; P:negative regulation of insulin receptor signaling pathway; ISS:BHF-UCL.
DR   GO; GO:0043407; P:negative regulation of MAP kinase activity; IMP:BHF-UCL.
DR   GO; GO:0050732; P:negative regulation of peptidyl-tyrosine phosphorylation; ISS:BHF-UCL.
DR   GO; GO:0090331; P:negative regulation of platelet aggregation; ISS:UniProtKB.
DR   GO; GO:0032091; P:negative regulation of protein binding; TAS:BHF-UCL.
DR   GO; GO:0042119; P:neutrophil activation; IDA:UniProtKB.
DR   GO; GO:0018105; P:peptidyl-serine phosphorylation; IDA:UniProtKB.
DR   GO; GO:0018107; P:peptidyl-threonine phosphorylation; IDA:UniProtKB.
DR   GO; GO:2001235; P:positive regulation of apoptotic signaling pathway; IEA:Ensembl.
DR   GO; GO:2000304; P:positive regulation of ceramide biosynthetic process; IMP:BHF-UCL.
DR   GO; GO:0032079; P:positive regulation of endodeoxyribonuclease activity; IMP:UniProtKB.
DR   GO; GO:2000753; P:positive regulation of glucosylceramide catabolic process; IMP:BHF-UCL.
DR   GO; GO:1900163; P:positive regulation of phospholipid scramblase activity; IMP:UniProtKB.
DR   GO; GO:0035307; P:positive regulation of protein dephosphorylation; IMP:BHF-UCL.
DR   GO; GO:0042307; P:positive regulation of protein import into nucleus; IMP:UniProtKB.
DR   GO; GO:2001022; P:positive regulation of response to DNA damage stimulus; IMP:UniProtKB.
DR   GO; GO:2000755; P:positive regulation of sphingomyelin catabolic process; IMP:BHF-UCL.
DR   GO; GO:0032930; P:positive regulation of superoxide anion generation; IMP:UniProtKB.
DR   GO; GO:0043687; P:post-translational protein modification; IDA:UniProtKB.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:0050821; P:protein stabilization; NAS:UniProtKB.
DR   GO; GO:0032956; P:regulation of actin cytoskeleton organization; IMP:CACAO.
DR   GO; GO:2000303; P:regulation of ceramide biosynthetic process; IDA:UniProtKB.
DR   GO; GO:0043488; P:regulation of mRNA stability; TAS:Reactome.
DR   GO; GO:0010469; P:regulation of signaling receptor activity; TAS:BHF-UCL.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   GO; GO:0023021; P:termination of signal transduction; IMP:BHF-UCL.
DR   CDD; cd00029; C1; 2.
DR   CDD; cd05620; STKc_nPKC_delta; 1.
DR   Gene3D; 2.60.40.150; -; 1.
DR   InterPro; IPR000961; AGC-kinase_C.
DR   InterPro; IPR046349; C1-like_sf.
DR   InterPro; IPR000008; C2_dom.
DR   InterPro; IPR035892; C2_domain_sf.
DR   InterPro; IPR020454; DAG/PE-bd.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR034667; nPKC_delta.
DR   InterPro; IPR002219; PE/DAG-bd.
DR   InterPro; IPR027436; PKC_delta.
DR   InterPro; IPR017892; Pkinase_C.
DR   InterPro; IPR014376; Prot_kin_PKC_delta.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF00130; C1_1; 2.
DR   Pfam; PF00069; Pkinase; 1.
DR   Pfam; PF00433; Pkinase_C; 1.
DR   PIRSF; PIRSF000551; PKC_delta; 1.
DR   PIRSF; PIRSF501104; Protein_kin_C_delta; 1.
DR   PRINTS; PR00008; DAGPEDOMAIN.
DR   SMART; SM00109; C1; 2.
DR   SMART; SM00133; S_TK_X; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF49562; SSF49562; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   SUPFAM; SSF57889; SSF57889; 2.
DR   PROSITE; PS51285; AGC_KINASE_CTER; 1.
DR   PROSITE; PS50004; C2; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
DR   PROSITE; PS00479; ZF_DAG_PE_1; 2.
DR   PROSITE; PS50081; ZF_DAG_PE_2; 2.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Apoptosis; ATP-binding; Cell cycle;
KW   Cell membrane; Cytoplasm; Kinase; Membrane; Metal-binding; Mitochondrion;
KW   Nucleotide-binding; Nucleus; Phosphoprotein; Reference proteome; Repeat;
KW   Serine/threonine-protein kinase; Transferase; Tumor suppressor; Zinc;
KW   Zinc-finger.
FT   CHAIN           1..676
FT                   /note="Protein kinase C delta type"
FT                   /id="PRO_0000055694"
FT   CHAIN           1..329
FT                   /note="Protein kinase C delta type regulatory subunit"
FT                   /evidence="ECO:0000250"
FT                   /id="PRO_0000421667"
FT   CHAIN           330..676
FT                   /note="Protein kinase C delta type catalytic subunit"
FT                   /evidence="ECO:0000250"
FT                   /id="PRO_0000421668"
FT   DOMAIN          1..106
FT                   /note="C2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00041"
FT   DOMAIN          349..603
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   DOMAIN          604..675
FT                   /note="AGC-kinase C-terminal"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00618"
FT   ZN_FING         158..208
FT                   /note="Phorbol-ester/DAG-type 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00226"
FT   ZN_FING         230..280
FT                   /note="Phorbol-ester/DAG-type 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00226"
FT   ACT_SITE        473
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000255|PROSITE-ProRule:PRU10027"
FT   BINDING         355..363
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         378
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   SITE            48
FT                   /note="Interaction with phosphotyrosine-containing peptide"
FT   SITE            62
FT                   /note="Interaction with phosphotyrosine-containing peptide"
FT   SITE            67
FT                   /note="Interaction with phosphotyrosine-containing peptide"
FT   SITE            123
FT                   /note="Interaction with phosphotyrosine-containing peptide"
FT   SITE            329..330
FT                   /note="Cleavage; by caspase-3"
FT                   /evidence="ECO:0000250"
FT   MOD_RES         43
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:P28867"
FT   MOD_RES         50
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000269|PubMed:17965192"
FT   MOD_RES         64
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000250|UniProtKB:P09215"
FT   MOD_RES         130
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   MOD_RES         141
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000269|PubMed:17965192,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         155
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000269|PubMed:15774464"
FT   MOD_RES         218
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:19369195"
FT   MOD_RES         299
FT                   /note="Phosphoserine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:17603046,
FT                   ECO:0007744|PubMed:18691976, ECO:0007744|PubMed:23186163"
FT   MOD_RES         302
FT                   /note="Phosphoserine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:17603046,
FT                   ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:23186163"
FT   MOD_RES         304
FT                   /note="Phosphoserine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:17603046,
FT                   ECO:0000269|PubMed:17965192, ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         307
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         313
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000269|PubMed:17570831,
FT                   ECO:0007744|PubMed:18691976, ECO:0007744|PubMed:19369195,
FT                   ECO:0007744|PubMed:19690332"
FT   MOD_RES         334
FT                   /note="Phosphotyrosine; by SRC"
FT                   /evidence="ECO:0000250|UniProtKB:P09215"
FT   MOD_RES         374
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0007744|PubMed:20068231"
FT   MOD_RES         451
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000269|PubMed:17965192"
FT   MOD_RES         503
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18691976,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         506
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:17965192"
FT   MOD_RES         507
FT                   /note="Phosphothreonine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:17965192,
FT                   ECO:0000305|PubMed:19801500"
FT   MOD_RES         567
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000269|PubMed:17570831"
FT   MOD_RES         645
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:19801500,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692"
FT   MOD_RES         654
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18691976"
FT   MOD_RES         658
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18691976"
FT   MOD_RES         664
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:17965192,
FT                   ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:18691976,
FT                   ECO:0007744|PubMed:19369195, ECO:0007744|PubMed:19690332,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:23186163,
FT                   ECO:0007744|PubMed:24275569"
FT   VAR_SEQ         328
FT                   /note="Q -> QGEAGSIAPLRFLFPLRPKKGDCPPFHCQVRQ (in isoform
FT                   2)"
FT                   /evidence="ECO:0000303|PubMed:18092819"
FT                   /id="VSP_043899"
FT   VARIANT         348
FT                   /note="N -> S (in dbSNP:rs33911937)"
FT                   /id="VAR_035347"
FT   VARIANT         375
FT                   /note="F -> S (in dbSNP:rs1056998)"
FT                   /evidence="ECO:0000269|PubMed:8357834"
FT                   /id="VAR_006175"
FT   VARIANT         410
FT                   /note="L -> F (in dbSNP:rs34502209)"
FT                   /id="VAR_035348"
FT   VARIANT         483
FT                   /note="R -> W (in dbSNP:rs35891605)"
FT                   /id="VAR_046009"
FT   VARIANT         494
FT                   /note="M -> V"
FT                   /evidence="ECO:0000269|PubMed:7988719"
FT                   /id="VAR_020610"
FT   VARIANT         593
FT                   /note="V -> M"
FT                   /evidence="ECO:0000269|PubMed:8357834"
FT                   /id="VAR_006176"
FT   MUTAGEN         299
FT                   /note="S->A: Loss of phosphorylation."
FT                   /evidence="ECO:0000269|PubMed:17603046"
FT   MUTAGEN         507
FT                   /note="T->A: No effect on kinase activity."
FT                   /evidence="ECO:0000269|PubMed:11772397"
FT   CONFLICT        524
FT                   /note="K -> R (in Ref. 2; BAG36031)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        533
FT                   /note="S -> A (in Ref. 8; no nucleotide entry)"
FT                   /evidence="ECO:0000305"
FT   STRAND          1..13
FT                   /evidence="ECO:0007829|PDB:1YRK"
FT   STRAND          20..23
FT                   /evidence="ECO:0007829|PDB:1YRK"
FT   STRAND          27..38
FT                   /evidence="ECO:0007829|PDB:1YRK"
FT   STRAND          41..45
FT                   /evidence="ECO:0007829|PDB:1YRK"
FT   STRAND          58..62
FT                   /evidence="ECO:0007829|PDB:1YRK"
FT   STRAND          68..76
FT                   /evidence="ECO:0007829|PDB:1YRK"
FT   STRAND          79..87
FT                   /evidence="ECO:0007829|PDB:1YRK"
FT   HELIX           88..96
FT                   /evidence="ECO:0007829|PDB:1YRK"
FT   TURN            97..100
FT                   /evidence="ECO:0007829|PDB:1YRK"
FT   STRAND          101..107
FT                   /evidence="ECO:0007829|PDB:1YRK"
FT   STRAND          109..111
FT                   /evidence="ECO:0007829|PDB:1YRK"
FT   STRAND          113..123
FT                   /evidence="ECO:0007829|PDB:1YRK"
FT   HELIX           156..158
FT                   /evidence="ECO:0007829|PDB:2YUU"
FT   STRAND          161..164
FT                   /evidence="ECO:0007829|PDB:2YUU"
FT   STRAND          173..175
FT                   /evidence="ECO:0007829|PDB:2YUU"
FT   STRAND          181..183
FT                   /evidence="ECO:0007829|PDB:2YUU"
FT   STRAND          186..189
FT                   /evidence="ECO:0007829|PDB:2YUU"
FT   TURN            190..192
FT                   /evidence="ECO:0007829|PDB:2YUU"
FT   HELIX           200..202
FT                   /evidence="ECO:0007829|PDB:2YUU"
SQ   SEQUENCE   676 AA;  77505 MW;  013F4314A2EE331A CRC64;
     MAPFLRIAFN SYELGSLQAE DEANQPFCAV KMKEALSTER GKTLVQKKPT MYPEWKSTFD
     AHIYEGRVIQ IVLMRAAEEP VSEVTVGVSV LAERCKKNNG KAEFWLDLQP QAKVLMSVQY
     FLEDVDCKQS MRSEDEAKFP TMNRRGAIKQ AKIHYIKNHE FIATFFGQPT FCSVCKDFVW
     GLNKQGYKCR QCNAAIHKKC IDKIIGRCTG TAANSRDTIF QKERFNIDMP HRFKVHNYMS
     PTFCDHCGSL LWGLVKQGLK CEDCGMNVHH KCREKVANLC GINQKLLAEA LNQVTQRASR
     RSDSASSEPV GIYQGFEKKT GVAGEDMQDN SGTYGKIWEG SSKCNINNFI FHKVLGKGSF
     GKVLLGELKG RGEYFAIKAL KKDVVLIDDD VECTMVEKRV LTLAAENPFL THLICTFQTK
     DHLFFVMEFL NGGDLMYHIQ DKGRFELYRA TFYAAEIMCG LQFLHSKGII YRDLKLDNVL
     LDRDGHIKIA DFGMCKENIF GESRASTFCG TPDYIAPEIL QGLKYTFSVD WWSFGVLLYE
     MLIGQSPFHG DDEDELFESI RVDTPHYPRW ITKESKDILE KLFEREPTKR LGVTGNIKIH
     PFFKTINWTL LEKRRLEPPF RPKVKSPRDY SNFDQEFLNE KARLSYSDKN LIDSMDQSAF
     AGFSFVNPKF EHLLED
//
